Health · 36 views
Novel drug shows promise in an early phase trial in heart failure
Health 
Story intelligence
Coverage Single outlet Single-outlet story
Views 36 Community interest
Brief read Under 1 min brief 32 words
Summary
The oral relaxin agonist AZD5462 improved cardiac function in patients with chronic heart failure, according to results presented in a Hot Line session at ESC Congress 2026 and published simultaneously in Circulation.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Patient-centered financial navigation assistance helps reduce financial toxicity among cancer patientsContinue reading
- Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar rangeContinue reading
- Wearing headphones during surgery may reduce nausea and vomiting afterwardContinue reading
- Adult ADHD; Encouraging Advance Care Planning; Hospital Closures in the U.S.Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow